ELI LILLY AND COMPANY
United States of America (US)
Rating OpenCorporation: 15.42 su 100
Ranking 2019: 454 su 602 aziende
Classificazione NACE primaria e secondaria:
• Manufacture of pharmaceutical preparations (2120)
• Research and experimental development on biotechnology (7211)
Descrizione dell'azienda
The company, with registered head office located in Indianapolis, United States, is a global pharmaceutical company engaged in the discovery, development, manufacture, and sale of pharmaceutical products. It was founded by Eli Lilly in 1876.The company is committed in developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier and more active lives. It offers neuroscience products that are used for the treatment of schizophrenia, bipolar mania, and maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; bulimia and obsessive-compulsive disorder; Parkinson's disease; bipolar depression; stress urinary incontinence; and pre-menstrual dysphoric disorder. The company also provides endocrine products, including injectable human insulin analogs and oral agents for the treatment of diabetes and osteoporosis in post-menopausal women and men for fracture; and an injectable for the treatment of human growth hormone deficiency and idiopathic short stature. In addition, the company manufactures oncology products that are used for the treatment of pancreatic cancer, bladder cancer, metastatic breast cancer, nonsmall cell lung cancer, ovarian cancer, and malignant pleural mesothelioma; and animal health products comprising cattle feed additives that controls and prevents coccidiosis, performance enhancers and antibiotics used to treat respiratory diseases, anticoccidial agents, antibiotics used to control enteric infections, and parasiticide for use on cattle and premises.Other offers include cardiovascular agents for use as an adjunct to percutaneous coronary intervention, including patients undergoing angioplasty and atherectomy or stent placement, as well as for the treatment of adults with sepsis at high risk of death; anti-infectives to treat staphylococcal and bacterial infections; and other pharmaceutical products for the treatment of erectile dysfunction.The company is one of the world's largest pharmaceutical corporations. It is also one of the oldest and leading pharmaceutical companies in the United States. The company has approximately 43,000 employees worldwide and it markets its medicines in 143 countries. The company has clinical research operations conducted in more than 50 countries, research and development facilities located in nine countries, and manufacturing plants located in 13 countries.The company's mission is to create and deliver superior health care solutions in order to provide customers around the world with optimal clinical and economic outcomes.
Questionario OpenCorporation
La versione in sola lettura del questionario inviato a questa azienda è disponibile pubblicamente: vedi questionario.